BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors

Blood

Volumn 88, Issue 6, 1996, Pages 2118-2124

  Pawelec, Graham ^a   Max, Heiner ^b   Halder, Thomas ^b   Bruserud, Øystein ^b   Merl, Andrea ^b   Da Silva, Paul ^b   Kalbacher, Hubert ^b  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; HLA DR ANTIGEN; HLA DR4 ANTIGEN;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0029815159     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.6.2118.bloodjournal8862118     Document Type: Article

References (25)

1. Juttner CA, Fibbe WE, Nemunaitis J, Kanz L, Gianni AM: Blood cell transplantation: Report from an international consensus meeting. Bone Marrow Transplant 14:689, 1994
2. Talpaz M: Use of interferon in the treatment of chronic myelogenous leukemia. Semin Oncol 21:3, 1994
3. Kantarjian HM, Talpaz M: Chemotherapy and bone marrow transplantation in the treatment of chronic myelogenous leukemia. Semin Oncol 21:8, 1994
4. Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb H-J, Rimm AA, Ringdén O, Rozman C, Speck B, Truitt RL, Zwaan FE, Bortin MM: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555, 1990
5. Falkenburg JHF, Goselink HM, Van der Harst D, Van Luxemburgheijs SAP, Kooywinkelaar YMC, Faber LM, De Kroon J, Brand A, Fibbe WE, Willemze R, Goulmy E: Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic lymphocytes-T. J Exp Med 174:27, 1991
6. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W: Immunity to oncogenic proteins. Immunol Rev 145:33, 1995
7. Cullis JO, Barrett AJ, Goldman JM, Lechler RI: Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules - Studies in antigen-processing defective cell lines. Leukemia 8:165, 1994
8. Bocchia M, Wentworth PA, Southwood S, Sidney J, McGraw K, Scheinberg DA, Sette A: Specific binding of leukemia oncogene fusion protein peptides to HLA class I molecules. Blood 85:2680, 1995
9. Ten Bosch GJA, Toornvliet AC, Friede T, Melief CJM, Leeksma OC: Recognition of peptides corresponding to the joining region of p210(BCR-ABL) protein by human T cells. Leukemia 9:1344, 1995
10. Valiron O, Clemancey-Marcille G, Troesch A, Schweitzer A, Prenant M, Hollard D, Berthier R: Immunophenotype of blast cells in chronic myeloid leukemia. Leuk Res 12:861, 1988
11. Pawelec G, Schmidt H, Schneider E, Bühring HJ, Ehninger G: Cellular immunological defects of chronic myelogenous leukaemia: Partial dependence on busulphan therapy. Cancer Immunol Immunother 27:89, 1988
12. Topalian SL: MHC class II restricted tumor antigens and the role of CD4(+) T cells in cancer immunotherapy. Curr Opin Immunol 6:741, 1994
13. Greenberg PD, Klarnet JP, Kern DE, Cheever MA: Therapy of disseminated tumour by adoptive transfer of specifically immune T cells. Prog Exp Tumor Rev Res 32:104, 1988
14. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicci PG, Parmiani G: Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RARalpha present in acute promyelocytic leukemia cells. Blood 81:1369, 1993
15. Kropshofer H, Max H, Kalbacher H: Evidence for cobinding of selfpeptide and allopeptide to human class-II major histocompatibility antigen DR1 by energy transfer. Proc Natl Acad Sci USA 90:403, 1993
16. Max H, Halder T, Kropshofer H, Kalbus M, Muller CA, Kalbacher H: Characterization of peptides bound to extracellular and intracellular HLA-DR1 molecules. Hum Immunol 38:193, 1993
17. Pawelec G, Rehbein A, Schlotz E, da Silva P: Cellular immune responses to autologous chronic myelogenous leukemia (CML) cells in vitro. Cancer Immunol Immunother 42:193, 1996
18. Pawelec G, Schneider E, Ehninger G, Rehbein A, Schmidt H: Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-α (Wellferon). Cancer Immunol Immunother 29:63, 1989
19. Schmidt H, Steinke B, Zinser R, Freese G, Gehr C, Gekeler V, Waller HD: Interferon a in the treatment of chronic myeloid leukemia and essential thrombocytosis: Differences in response rate between untreated patients and patients pretreated with busulfan. Tumor Diagn Ther 10:257, 1989
20. Pawelec G, Busch FW: Pretreatment of chronic myelogenous leukaemic blood samples with cytosine arabinoside prior to mixed lymphocyte culture typing. Transplantation 46:607, 1988
21. Gedde-Dahl T III, Eriksen JA, Thorsby E, Gaudernack G: T-cell responses against products of oncogenes: Generation and characterization of human T-cell clones specific for p21 ras-derived peptides. Hum Immunol 33:266, 1992
22. Sansom DM, Wilson A, Boshell M, Lewis J, Hall ND: B7/ CD28 but not LFA-3/CD2 interactions can provide 3rd-party costimulation for human T-cell activation. Immunology 80:242, 1993
23. Pawelec G, Shaw S, Ziegler A, Müller C, Wernet P: Differential inhibition of HLA-D or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. J Immunol 129:1070, 1982
24. Chen W, Peace DJ, Rovira DK, You SG, Cheever MA: T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 89:1468, 1992
25. Rosenkrantz K, Dupont B, Flomenberg N: Generation and regulation of autocytotoxicity in mixed lymphocyte cultures: Evidence for active suppression of autocytotoxic cells. Proc Natl Acad Sci USA 82:4508, 1985